Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Pei Li Teh & Wan Ling Neo
  • November 15, 2019
  • Articles

Launching novel oncology therapies in Asia: Identifying and communicating value

Launching novel oncology therapies in Asia: Identifying and communicating value

Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success. 

read more »

  • Posted by Dr. Chris Gaj
  • June 25, 2019
  • Articles

The Promise and Pitfalls of Molecular Testing in Oncology

 The Promise and Pitfalls of Molecular Testing in Oncology

Dr. Chris Gaj explores the challenges and potential consequences for stakeholders in the US, Europe and emerging markets in the latest issue of pharmaphorum's Deep Dive (Published June 2019).

Early targeted therapies, such as the tyrosine kinase inhibitor erlotinib from Roche/Genentech/OSI, offered the promise of precision medicine to treat cancer at a molecular level. Oncologists noted individual “Lazarus-like” responses to erlotinib, but overall effectiveness was moderate in unselected populations. It was not until the discovery that specific activating mutations in the epidermal growth factor receptor (EGFr) conveyed sensitivity to erlotinib that oncologists could identify the patients most likely to respond and target them for treatment while limiting exposure to those unlikely to respond.

read more »

  • Posted by Pei Li Teh
  • December 12, 2018
  • Webinars

Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies

Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies

Novel cancer therapies are offering patients new treatments and better outcomes worldwide. And recent changes in healthcare policies across APAC, such as China’s fast tracking approval of therapies for severe and rare diseases, have reignited interest in the APAC region as a strong market for oncology. 

read more »

  • Posted by Anthony Greenwood, Dr Chris Gaj, Brett Gardiner
  • May 18, 2018
  • Webinars

Combination therapies in oncology: The benefits of integrated insights

Combination therapies in oncology: The benefits of integrated insights

In association with Pharmaceutical Executive

Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.
 

read more »

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment -and wanted to better understand the disease and treatment challenges faced by both patients and physicians across Asia. In addition, our client also wanted to establish KOLs to advocate for the management of OM by raising the overall disease awareness, understanding and provision of better support for the wider healthcare community. In order to achieve this our client intended to submit the research for publication in a leading medical journal.

read more »